ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 132 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.88 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,032,951 | +258.6% | 361,052 | +587.1% | 0.00% | +300.0% |
| Q2 2023 | $1,124,549 | +409.9% | 52,549 | +1008.4% | 0.00% | – |
| Q4 2022 | $220,551 | -10.3% | 4,741 | 0.0% | 0.00% | – |
| Q3 2022 | $246,000 | +9.8% | 4,741 | 0.0% | 0.00% | – |
| Q2 2022 | $224,000 | -48.5% | 4,741 | -22.3% | 0.00% | – |
| Q1 2022 | $435,000 | -76.3% | 6,105 | -75.1% | 0.00% | -100.0% |
| Q4 2021 | $1,833,000 | +212.3% | 24,508 | +137.1% | 0.00% | +100.0% |
| Q3 2021 | $587,000 | -46.1% | 10,336 | -58.2% | 0.00% | 0.0% |
| Q2 2021 | $1,089,000 | -46.4% | 24,740 | -39.9% | 0.00% | -50.0% |
| Q1 2021 | $2,031,000 | +117.2% | 41,184 | +85.4% | 0.00% | +100.0% |
| Q4 2020 | $935,000 | -16.1% | 22,209 | -8.7% | 0.00% | 0.0% |
| Q3 2020 | $1,114,000 | +49.7% | 24,326 | +64.2% | 0.00% | 0.0% |
| Q2 2020 | $744,000 | +44.7% | 14,814 | +48.1% | 0.00% | 0.0% |
| Q1 2020 | $514,000 | -53.9% | 10,000 | -44.7% | 0.00% | -50.0% |
| Q4 2019 | $1,116,000 | -12.8% | 18,068 | -15.2% | 0.00% | 0.0% |
| Q3 2019 | $1,280,000 | +466.4% | 21,297 | +693.8% | 0.00% | – |
| Q2 2019 | $226,000 | -39.2% | 2,683 | -48.9% | 0.00% | -100.0% |
| Q4 2018 | $372,000 | -73.5% | 5,250 | -68.1% | 0.00% | -50.0% |
| Q3 2018 | $1,406,000 | -74.3% | 16,450 | -65.2% | 0.00% | -75.0% |
| Q2 2018 | $5,478,000 | +49.5% | 47,265 | +4.4% | 0.01% | +60.0% |
| Q1 2018 | $3,665,000 | +366.9% | 45,291 | +238.6% | 0.01% | +400.0% |
| Q4 2017 | $785,000 | -14.6% | 13,374 | -31.9% | 0.00% | 0.0% |
| Q3 2017 | $919,000 | -34.1% | 19,632 | -49.3% | 0.00% | -50.0% |
| Q2 2017 | $1,394,000 | +186.2% | 38,736 | +145.1% | 0.00% | +100.0% |
| Q1 2017 | $487,000 | -53.1% | 15,806 | -49.0% | 0.00% | -50.0% |
| Q4 2016 | $1,038,000 | -55.3% | 30,990 | -64.5% | 0.00% | -50.0% |
| Q3 2016 | $2,324,000 | +937.5% | 87,339 | +1439.6% | 0.00% | – |
| Q3 2014 | $224,000 | – | 5,673 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 858,811 | $36,156,000 | 10.56% |
| Fairmount Funds Management LLC | 150,433 | $6,333,000 | 2.26% |
| ARMISTICE CAPITAL, LLC | 1,356,000 | $57,088,000 | 1.94% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,775,000 | $74,728,000 | 0.45% |
| Virtus ETF Advisers LLC | 14,321 | $603,000 | 0.25% |
| Granahan Investment Management | 231,071 | $9,728,000 | 0.22% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 248,320 | $10,454,000 | 0.09% |
| ACADIAN ASSET MANAGEMENT LLC | 467,514 | $19,684,000 | 0.08% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 126 | $5,000 | 0.08% |
| AIGEN INVESTMENT MANAGEMENT, LP | 12,854 | $541,000 | 0.07% |